| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 55 | 2023 | 21683 | 1.970 |
Why?
|
| Protein-Arginine N-Methyltransferases | 4 | 2021 | 131 | 1.580 |
Why?
|
| Phosphoric Monoester Hydrolases | 10 | 2004 | 431 | 1.400 |
Why?
|
| Cell Line, Tumor | 78 | 2023 | 16689 | 1.300 |
Why?
|
| PTEN Phosphohydrolase | 19 | 2015 | 1142 | 1.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 18 | 2023 | 2938 | 1.030 |
Why?
|
| Antineoplastic Agents | 27 | 2021 | 13695 | 1.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 5 | 2021 | 538 | 1.010 |
Why?
|
| MAP Kinase Signaling System | 8 | 2021 | 1526 | 0.990 |
Why?
|
| Xenograft Model Antitumor Assays | 23 | 2020 | 3557 | 0.980 |
Why?
|
| Oncogenes | 8 | 2017 | 1265 | 0.970 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2014 | 4554 | 0.970 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 6 | 2018 | 380 | 0.910 |
Why?
|
| Acidaminococcus | 1 | 2022 | 9 | 0.870 |
Why?
|
| Tumor Suppressor Proteins | 14 | 2004 | 2849 | 0.860 |
Why?
|
| Genes, Tumor Suppressor | 10 | 2010 | 1097 | 0.840 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2021 | 13 | 0.840 |
Why?
|
| Aminopyridines | 7 | 2017 | 542 | 0.840 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2021 | 47 | 0.830 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2021 | 73 | 0.810 |
Why?
|
| Genes, Essential | 2 | 2021 | 183 | 0.810 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 2727 | 0.800 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2020 | 5172 | 0.760 |
Why?
|
| Pyrimidines | 11 | 2018 | 2942 | 0.640 |
Why?
|
| ras Proteins | 5 | 2018 | 1060 | 0.630 |
Why?
|
| Research Personnel | 1 | 2023 | 573 | 0.630 |
Why?
|
| Allosteric Site | 2 | 2017 | 103 | 0.620 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 3 | 2008 | 76 | 0.600 |
Why?
|
| Purines | 2 | 2017 | 594 | 0.580 |
Why?
|
| Retinoblastoma Protein | 9 | 2005 | 704 | 0.580 |
Why?
|
| Prostatic Neoplasms | 21 | 2008 | 11124 | 0.580 |
Why?
|
| Cyclin-Dependent Kinase 6 | 4 | 2021 | 322 | 0.570 |
Why?
|
| Mice, Nude | 21 | 2021 | 3689 | 0.570 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2017 | 434 | 0.570 |
Why?
|
| Proto-Oncogene Proteins c-akt | 19 | 2013 | 2503 | 0.560 |
Why?
|
| Genetic Techniques | 1 | 2019 | 435 | 0.560 |
Why?
|
| Purine-Nucleoside Phosphorylase | 1 | 2016 | 27 | 0.550 |
Why?
|
| Transcription Factors | 24 | 2018 | 12208 | 0.550 |
Why?
|
| Mutation | 40 | 2023 | 29786 | 0.550 |
Why?
|
| DNA-Binding Proteins | 22 | 2018 | 9648 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 27 | 2020 | 8428 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 25 | 2023 | 5535 | 0.540 |
Why?
|
| Signal Transduction | 36 | 2021 | 23403 | 0.540 |
Why?
|
| Cell Lineage | 8 | 2018 | 2504 | 0.540 |
Why?
|
| Gene Amplification | 12 | 2016 | 1063 | 0.540 |
Why?
|
| Cell Cycle | 15 | 2017 | 2967 | 0.530 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2018 | 2948 | 0.530 |
Why?
|
| Imidazoles | 2 | 2019 | 1206 | 0.520 |
Why?
|
| RNA Interference | 5 | 2017 | 2889 | 0.520 |
Why?
|
| Gene Dosage | 12 | 2015 | 1252 | 0.510 |
Why?
|
| Proto-Oncogene Proteins B-raf | 10 | 2023 | 2043 | 0.500 |
Why?
|
| Niacinamide | 1 | 2017 | 417 | 0.500 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2019 | 1375 | 0.500 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 17 | 2015 | 3920 | 0.490 |
Why?
|
| Pyrroles | 2 | 2018 | 1146 | 0.480 |
Why?
|
| RNA, Small Interfering | 10 | 2018 | 3505 | 0.470 |
Why?
|
| Methionine | 1 | 2016 | 590 | 0.450 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 4 | 2020 | 234 | 0.450 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2013 | 101 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 705 | 0.430 |
Why?
|
| High-Throughput Screening Assays | 5 | 2016 | 944 | 0.430 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 5 | 2010 | 252 | 0.430 |
Why?
|
| Neoplasm Transplantation | 11 | 2018 | 2085 | 0.420 |
Why?
|
| Protein Kinases | 5 | 2008 | 1640 | 0.410 |
Why?
|
| Receptors, Fibroblast Growth Factor | 4 | 2013 | 185 | 0.410 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 689 | 0.410 |
Why?
|
| Cell Proliferation | 22 | 2023 | 10481 | 0.400 |
Why?
|
| Genomics | 7 | 2016 | 5720 | 0.400 |
Why?
|
| Melanoma | 11 | 2019 | 5510 | 0.390 |
Why?
|
| Neoplasm Proteins | 3 | 2021 | 3703 | 0.390 |
Why?
|
| Mice | 61 | 2021 | 81183 | 0.380 |
Why?
|
| Gene Expression Profiling | 22 | 2020 | 9438 | 0.370 |
Why?
|
| Humans | 166 | 2023 | 744343 | 0.360 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 3 | 2008 | 323 | 0.360 |
Why?
|
| Chromosome Aberrations | 5 | 2011 | 1813 | 0.360 |
Why?
|
| Animals | 81 | 2021 | 168757 | 0.350 |
Why?
|
| Genome, Human | 7 | 2016 | 4420 | 0.340 |
Why?
|
| Enzyme Activation | 11 | 2021 | 3701 | 0.340 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2023 | 1660 | 0.340 |
Why?
|
| Loss of Heterozygosity | 5 | 2008 | 684 | 0.330 |
Why?
|
| Cell Cycle Proteins | 12 | 2005 | 3462 | 0.330 |
Why?
|
| Colorectal Neoplasms | 4 | 2023 | 6773 | 0.320 |
Why?
|
| Pyrazoles | 4 | 2017 | 1972 | 0.320 |
Why?
|
| Repressor Proteins | 9 | 2018 | 3023 | 0.320 |
Why?
|
| Phosphorylation | 20 | 2021 | 8436 | 0.310 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 4 | 2014 | 188 | 0.310 |
Why?
|
| Thiazoles | 2 | 2014 | 1483 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2019 | 578 | 0.300 |
Why?
|
| DNA, Neoplasm | 11 | 2011 | 1758 | 0.300 |
Why?
|
| Cell Survival | 12 | 2018 | 5882 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 21 | 2016 | 15519 | 0.280 |
Why?
|
| Protein Binding | 18 | 2021 | 9386 | 0.280 |
Why?
|
| HCT116 Cells | 5 | 2021 | 408 | 0.280 |
Why?
|
| Transcription, Genetic | 13 | 2018 | 7722 | 0.280 |
Why?
|
| Apoptosis | 14 | 2018 | 9727 | 0.270 |
Why?
|
| Morpholines | 5 | 2014 | 571 | 0.270 |
Why?
|
| Benzamides | 8 | 2019 | 1379 | 0.260 |
Why?
|
| Carrier Proteins | 9 | 2001 | 5021 | 0.260 |
Why?
|
| Allosteric Regulation | 5 | 2020 | 408 | 0.260 |
Why?
|
| Software | 2 | 2019 | 4443 | 0.260 |
Why?
|
| Quinazolines | 8 | 2015 | 1356 | 0.260 |
Why?
|
| Fibroblast Growth Factors | 3 | 2019 | 879 | 0.250 |
Why?
|
| beta Catenin | 4 | 2023 | 1059 | 0.250 |
Why?
|
| Phosphoproteins | 6 | 2021 | 2440 | 0.250 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2015 | 59 | 0.250 |
Why?
|
| Bacillus Phages | 1 | 2004 | 12 | 0.250 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 6 | 2023 | 648 | 0.250 |
Why?
|
| Histones | 3 | 2021 | 2599 | 0.230 |
Why?
|
| MAP Kinase Kinase Kinases | 4 | 2018 | 261 | 0.230 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2219 | 0.230 |
Why?
|
| Epithelial Cells | 7 | 2016 | 3690 | 0.230 |
Why?
|
| Staurosporine | 1 | 2004 | 251 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 7 | 2015 | 6171 | 0.220 |
Why?
|
| Alleles | 7 | 2010 | 6933 | 0.220 |
Why?
|
| Cell Line | 17 | 2013 | 15997 | 0.220 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2016 | 2109 | 0.220 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 730 | 0.220 |
Why?
|
| Proteins | 4 | 2004 | 6103 | 0.220 |
Why?
|
| Receptors, Androgen | 4 | 2016 | 1058 | 0.210 |
Why?
|
| Drug Discovery | 2 | 2021 | 1058 | 0.210 |
Why?
|
| Mutation, Missense | 7 | 2011 | 2564 | 0.210 |
Why?
|
| Kynurenine | 2 | 2019 | 139 | 0.200 |
Why?
|
| Cell Division | 7 | 2009 | 4568 | 0.200 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 5221 | 0.200 |
Why?
|
| Protein Structure, Tertiary | 12 | 2016 | 3846 | 0.200 |
Why?
|
| bcl-X Protein | 3 | 2018 | 411 | 0.200 |
Why?
|
| Activin Receptors, Type II | 1 | 2001 | 127 | 0.190 |
Why?
|
| Spliceosomes | 1 | 2021 | 110 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 13 | 2020 | 6314 | 0.190 |
Why?
|
| Transcriptional Activation | 5 | 2002 | 1783 | 0.190 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2004 | 486 | 0.190 |
Why?
|
| Methylation | 2 | 2021 | 1106 | 0.190 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2017 | 2942 | 0.190 |
Why?
|
| Genes, Retinoblastoma | 2 | 1997 | 136 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2018 | 776 | 0.180 |
Why?
|
| Gene Knockout Techniques | 2 | 2021 | 809 | 0.180 |
Why?
|
| Rhabdoid Tumor | 2 | 2013 | 212 | 0.180 |
Why?
|
| Gene Library | 4 | 2017 | 1074 | 0.180 |
Why?
|
| Lung Neoplasms | 13 | 2023 | 13102 | 0.180 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2019 | 17 | 0.180 |
Why?
|
| Streptococcus pyogenes | 1 | 2022 | 289 | 0.180 |
Why?
|
| Stomach Neoplasms | 3 | 2019 | 1333 | 0.180 |
Why?
|
| RNA, Messenger | 6 | 2009 | 13033 | 0.180 |
Why?
|
| Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor | 1 | 2019 | 10 | 0.180 |
Why?
|
| Pyridazines | 1 | 2021 | 202 | 0.180 |
Why?
|
| Gene Knockdown Techniques | 4 | 2019 | 1655 | 0.170 |
Why?
|
| Phenylurea Compounds | 2 | 2013 | 528 | 0.170 |
Why?
|
| Rats | 10 | 2020 | 24260 | 0.170 |
Why?
|
| raf Kinases | 2 | 2018 | 122 | 0.170 |
Why?
|
| Piperidines | 3 | 2016 | 1602 | 0.170 |
Why?
|
| Nuclear Proteins | 8 | 2021 | 5853 | 0.170 |
Why?
|
| Asparagine | 1 | 2019 | 122 | 0.170 |
Why?
|
| Inhibitory Concentration 50 | 3 | 2016 | 459 | 0.170 |
Why?
|
| Pyrazines | 2 | 2016 | 1230 | 0.170 |
Why?
|
| HEK293 Cells | 5 | 2021 | 4204 | 0.170 |
Why?
|
| Protein Conformation | 6 | 2016 | 4011 | 0.170 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2016 | 625 | 0.170 |
Why?
|
| Models, Molecular | 11 | 2021 | 5456 | 0.170 |
Why?
|
| Prostate | 6 | 2016 | 1774 | 0.160 |
Why?
|
| Cell Death | 3 | 2015 | 1706 | 0.160 |
Why?
|
| 2,2'-Dipyridyl | 1 | 2018 | 11 | 0.160 |
Why?
|
| GTP Phosphohydrolases | 1 | 2021 | 509 | 0.160 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 561 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2018 | 365 | 0.160 |
Why?
|
| Retinoblastoma | 2 | 1998 | 318 | 0.160 |
Why?
|
| Asparaginase | 1 | 2019 | 236 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 497 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2021 | 2915 | 0.150 |
Why?
|
| G1 Phase | 6 | 2006 | 415 | 0.150 |
Why?
|
| Molecular Sequence Data | 18 | 2015 | 18111 | 0.150 |
Why?
|
| DNA Methylation | 3 | 2019 | 4286 | 0.150 |
Why?
|
| Models, Biological | 9 | 2015 | 9583 | 0.150 |
Why?
|
| Liver Neoplasms | 4 | 2019 | 4253 | 0.150 |
Why?
|
| Receptor, erbB-2 | 4 | 2013 | 2416 | 0.150 |
Why?
|
| Protein Array Analysis | 1 | 2019 | 411 | 0.150 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2013 | 736 | 0.140 |
Why?
|
| Triazines | 1 | 2019 | 315 | 0.140 |
Why?
|
| Epistasis, Genetic | 1 | 2019 | 365 | 0.140 |
Why?
|
| Kidney Neoplasms | 4 | 2019 | 4262 | 0.140 |
Why?
|
| Cytoplasm | 1 | 2021 | 1539 | 0.140 |
Why?
|
| Thionucleosides | 1 | 2016 | 13 | 0.140 |
Why?
|
| Gene Deletion | 5 | 2016 | 2751 | 0.140 |
Why?
|
| Deoxyadenosines | 1 | 2016 | 27 | 0.140 |
Why?
|
| Ion Channels | 1 | 2021 | 1056 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2018 | 1654 | 0.140 |
Why?
|
| Janus Kinase 2 | 3 | 2015 | 528 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 892 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 6538 | 0.140 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2015 | 390 | 0.130 |
Why?
|
| Retinal Neoplasms | 1 | 1997 | 144 | 0.130 |
Why?
|
| Genes, ras | 5 | 2012 | 690 | 0.130 |
Why?
|
| Genes, erbB-1 | 3 | 2005 | 161 | 0.130 |
Why?
|
| E2F Transcription Factors | 9 | 2005 | 277 | 0.130 |
Why?
|
| Genome | 3 | 2016 | 1808 | 0.130 |
Why?
|
| Base Sequence | 16 | 2016 | 12797 | 0.130 |
Why?
|
| Blotting, Western | 10 | 2014 | 5179 | 0.130 |
Why?
|
| Multiprotein Complexes | 3 | 2017 | 1119 | 0.130 |
Why?
|
| Disease Models, Animal | 8 | 2017 | 18029 | 0.130 |
Why?
|
| Caspases | 2 | 2014 | 928 | 0.130 |
Why?
|
| Diphenylamine | 3 | 2010 | 50 | 0.130 |
Why?
|
| Cell Differentiation | 10 | 2016 | 11483 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2021 | 2916 | 0.130 |
Why?
|
| Prostatectomy | 1 | 2003 | 1890 | 0.120 |
Why?
|
| Immunoblotting | 5 | 2013 | 1682 | 0.120 |
Why?
|
| Catalytic Domain | 1 | 2017 | 698 | 0.120 |
Why?
|
| Tankyrases | 1 | 2014 | 14 | 0.120 |
Why?
|
| Retinoblastoma-Binding Protein 1 | 8 | 1998 | 142 | 0.120 |
Why?
|
| Trans-Activators | 7 | 2005 | 2924 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2021 | 434 | 0.120 |
Why?
|
| Chromosome Deletion | 4 | 2008 | 1401 | 0.120 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2013 | 114 | 0.120 |
Why?
|
| RNA Splicing | 1 | 2019 | 907 | 0.120 |
Why?
|
| Breast Neoplasms | 8 | 2021 | 20822 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 890 | 0.120 |
Why?
|
| Research | 1 | 2023 | 1999 | 0.120 |
Why?
|
| Adenovirus E1A Proteins | 3 | 2005 | 76 | 0.120 |
Why?
|
| Mutagenesis, Insertional | 1 | 2017 | 655 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 2005 | 323 | 0.120 |
Why?
|
| Membrane Proteins | 4 | 2021 | 7880 | 0.120 |
Why?
|
| Genetic Vectors | 3 | 2017 | 3420 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 8 | 2013 | 5867 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 5 | 2015 | 5256 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 1990 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2016 | 1581 | 0.120 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2015 | 136 | 0.120 |
Why?
|
| Malformations of Cortical Development | 1 | 2016 | 200 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2022 | 1451 | 0.120 |
Why?
|
| Carcinoma | 3 | 2015 | 2375 | 0.120 |
Why?
|
| Cadherins | 2 | 2017 | 907 | 0.120 |
Why?
|
| Mice, SCID | 7 | 2014 | 2716 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2015 | 367 | 0.110 |
Why?
|
| Transcription Factor DP1 | 7 | 1998 | 141 | 0.110 |
Why?
|
| Mosaicism | 1 | 2016 | 441 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 11524 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 8 | 2013 | 4803 | 0.110 |
Why?
|
| DNA Transposable Elements | 1 | 2017 | 748 | 0.110 |
Why?
|
| Gene Targeting | 2 | 2009 | 880 | 0.110 |
Why?
|
| Computational Biology | 2 | 2016 | 3521 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2013 | 66 | 0.110 |
Why?
|
| Sulfonamides | 5 | 2014 | 1938 | 0.110 |
Why?
|
| Cyclins | 3 | 2002 | 603 | 0.110 |
Why?
|
| Proteomics | 3 | 2021 | 3638 | 0.110 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2005 | 671 | 0.110 |
Why?
|
| Protein Multimerization | 5 | 2018 | 970 | 0.110 |
Why?
|
| Androgens | 3 | 2004 | 1281 | 0.110 |
Why?
|
| Transfection | 10 | 2008 | 5892 | 0.110 |
Why?
|
| Ovarian Neoplasms | 3 | 2020 | 4838 | 0.110 |
Why?
|
| Glioma | 1 | 2007 | 3401 | 0.110 |
Why?
|
| Neuregulin-1 | 1 | 2013 | 142 | 0.110 |
Why?
|
| Receptor, erbB-3 | 1 | 2013 | 142 | 0.110 |
Why?
|
| Encyclopedias as Topic | 1 | 2012 | 20 | 0.110 |
Why?
|
| Metabolome | 1 | 2019 | 895 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2008 | 2649 | 0.100 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2012 | 105 | 0.100 |
Why?
|
| Female | 37 | 2021 | 380194 | 0.100 |
Why?
|
| Phenylthiohydantoin | 1 | 2013 | 193 | 0.100 |
Why?
|
| NIH 3T3 Cells | 6 | 2013 | 677 | 0.100 |
Why?
|
| DNA Mutational Analysis | 4 | 2011 | 4186 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2004 | 3523 | 0.100 |
Why?
|
| Antibodies | 2 | 2010 | 2460 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2013 | 215 | 0.100 |
Why?
|
| Reproducibility of Results | 7 | 2016 | 19905 | 0.100 |
Why?
|
| Male | 37 | 2021 | 350118 | 0.100 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 233 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2019 | 2309 | 0.100 |
Why?
|
| Structure-Activity Relationship | 4 | 2021 | 3129 | 0.100 |
Why?
|
| Genes, APC | 1 | 2011 | 159 | 0.100 |
Why?
|
| Pyruvate Kinase | 1 | 2012 | 189 | 0.100 |
Why?
|
| Janus Kinases | 1 | 2012 | 244 | 0.100 |
Why?
|
| Metabolomics | 1 | 2019 | 1484 | 0.100 |
Why?
|
| Transplantation, Heterologous | 6 | 2012 | 2382 | 0.090 |
Why?
|
| Cyclin D1 | 2 | 2010 | 463 | 0.090 |
Why?
|
| Immunoconjugates | 1 | 2018 | 901 | 0.090 |
Why?
|
| Serine Endopeptidases | 1 | 2016 | 1072 | 0.090 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2013 | 548 | 0.090 |
Why?
|
| Drug Design | 3 | 2019 | 1076 | 0.090 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 334 | 0.090 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2010 | 115 | 0.090 |
Why?
|
| DNA Primers | 7 | 2013 | 2892 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2021 | 63114 | 0.090 |
Why?
|
| Mutagenesis, Site-Directed | 5 | 2005 | 1723 | 0.090 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2010 | 63 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 3143 | 0.090 |
Why?
|
| Benzimidazoles | 3 | 2012 | 850 | 0.090 |
Why?
|
| Proteome | 1 | 2020 | 1799 | 0.090 |
Why?
|
| Adenocarcinoma | 7 | 2011 | 6364 | 0.090 |
Why?
|
| NF-kappa B | 2 | 2013 | 2499 | 0.090 |
Why?
|
| Doxycycline | 2 | 2009 | 326 | 0.090 |
Why?
|
| Gene Expression Regulation | 7 | 2016 | 12072 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 670 | 0.080 |
Why?
|
| Myeloproliferative Disorders | 1 | 2015 | 606 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2017 | 1226 | 0.080 |
Why?
|
| Peptides | 1 | 2021 | 4409 | 0.080 |
Why?
|
| Amino Acid Sequence | 8 | 2009 | 13815 | 0.080 |
Why?
|
| Interleukin-3 | 3 | 2005 | 444 | 0.080 |
Why?
|
| Glycolysis | 1 | 2012 | 827 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 1708 | 0.080 |
Why?
|
| Endometrial Neoplasms | 2 | 2008 | 1353 | 0.080 |
Why?
|
| Phenotype | 7 | 2016 | 16365 | 0.080 |
Why?
|
| Chromosome Mapping | 4 | 2007 | 4740 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2010 | 1285 | 0.080 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2009 | 152 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 2126 | 0.080 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2009 | 337 | 0.080 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2007 | 63 | 0.080 |
Why?
|
| Cell Polarity | 2 | 2008 | 645 | 0.080 |
Why?
|
| Information Dissemination | 1 | 2016 | 1099 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2000 | 5097 | 0.070 |
Why?
|
| Liposarcoma | 1 | 2010 | 333 | 0.070 |
Why?
|
| Indoles | 2 | 2013 | 1839 | 0.070 |
Why?
|
| Molecular Structure | 3 | 2021 | 1899 | 0.070 |
Why?
|
| Pyridones | 1 | 2012 | 712 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2013 | 4751 | 0.070 |
Why?
|
| Molecular Weight | 1 | 2009 | 2255 | 0.070 |
Why?
|
| In Situ Hybridization | 3 | 2010 | 1950 | 0.070 |
Why?
|
| Macaca fascicularis | 2 | 2020 | 915 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 6489 | 0.070 |
Why?
|
| Precipitin Tests | 3 | 2005 | 829 | 0.070 |
Why?
|
| Mass Spectrometry | 3 | 2021 | 2203 | 0.070 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2008 | 443 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2010 | 721 | 0.070 |
Why?
|
| Genotype | 6 | 2009 | 12951 | 0.070 |
Why?
|
| Quinolines | 1 | 2011 | 732 | 0.070 |
Why?
|
| Lentivirus | 1 | 2009 | 501 | 0.070 |
Why?
|
| Forkhead Transcription Factors | 3 | 2003 | 1613 | 0.070 |
Why?
|
| Piperazines | 2 | 2015 | 2488 | 0.070 |
Why?
|
| Saposins | 1 | 2005 | 27 | 0.070 |
Why?
|
| Point Mutation | 1 | 2011 | 1623 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2009 | 959 | 0.070 |
Why?
|
| Down-Regulation | 3 | 2002 | 3002 | 0.070 |
Why?
|
| Kinetics | 3 | 2022 | 6473 | 0.070 |
Why?
|
| Homozygote | 3 | 2005 | 1785 | 0.070 |
Why?
|
| E2F1 Transcription Factor | 5 | 1996 | 190 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2000 | 1086 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2005 | 2455 | 0.060 |
Why?
|
| Pyridines | 2 | 2015 | 2825 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2010 | 683 | 0.060 |
Why?
|
| Probability | 2 | 2007 | 2505 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 658 | 0.060 |
Why?
|
| Genetic Engineering | 1 | 2011 | 951 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 3508 | 0.060 |
Why?
|
| Oncogene Proteins | 2 | 2006 | 749 | 0.060 |
Why?
|
| STAT3 Transcription Factor | 2 | 2006 | 873 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 1827 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2002 | 133 | 0.060 |
Why?
|
| Sequence Deletion | 4 | 2006 | 1526 | 0.060 |
Why?
|
| Glioblastoma | 4 | 2019 | 3481 | 0.060 |
Why?
|
| Haplotypes | 3 | 2006 | 2779 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2015 | 1634 | 0.060 |
Why?
|
| Enzyme Inhibitors | 4 | 2020 | 3798 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 1519 | 0.060 |
Why?
|
| Amino Acid Substitution | 3 | 2011 | 1791 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2012 | 7729 | 0.060 |
Why?
|
| Noonan Syndrome | 1 | 2004 | 122 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2021 | 10943 | 0.060 |
Why?
|
| Gene Expression | 2 | 2015 | 7799 | 0.060 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 399 | 0.060 |
Why?
|
| Homeostasis | 2 | 2013 | 3340 | 0.060 |
Why?
|
| Hydrogen Bonding | 1 | 2004 | 293 | 0.060 |
Why?
|
| Thrombocythemia, Essential | 1 | 2005 | 105 | 0.060 |
Why?
|
| Cluster Analysis | 3 | 2008 | 2715 | 0.060 |
Why?
|
| Clinical Trials as Topic | 4 | 2019 | 7913 | 0.060 |
Why?
|
| Mice, Inbred NOD | 3 | 2014 | 1878 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 2 | 2008 | 287 | 0.060 |
Why?
|
| Polycythemia Vera | 1 | 2005 | 164 | 0.060 |
Why?
|
| Cells, Cultured | 8 | 2016 | 19229 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 1549 | 0.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2004 | 627 | 0.060 |
Why?
|
| Mutagenesis | 3 | 2013 | 1266 | 0.060 |
Why?
|
| Genes, Homeobox | 1 | 2004 | 286 | 0.060 |
Why?
|
| Binding Sites | 8 | 2012 | 6114 | 0.060 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2003 | 104 | 0.060 |
Why?
|
| Ligands | 1 | 2010 | 3282 | 0.060 |
Why?
|
| Microarray Analysis | 3 | 2013 | 767 | 0.060 |
Why?
|
| Species Specificity | 1 | 2007 | 2478 | 0.060 |
Why?
|
| Microcephaly | 1 | 2007 | 432 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 643 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2010 | 1222 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2019 | 3752 | 0.060 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 708 | 0.050 |
Why?
|
| Carcinoma, Small Cell | 1 | 2005 | 420 | 0.050 |
Why?
|
| Mice, Transgenic | 3 | 2004 | 9734 | 0.050 |
Why?
|
| Patient Selection | 1 | 2015 | 4215 | 0.050 |
Why?
|
| Primary Myelofibrosis | 1 | 2005 | 215 | 0.050 |
Why?
|
| Isoenzymes | 2 | 2011 | 1726 | 0.050 |
Why?
|
| S Phase | 3 | 2000 | 423 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 473 | 0.050 |
Why?
|
| Genes, p53 | 2 | 2008 | 755 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 3 | 2015 | 2012 | 0.050 |
Why?
|
| Cell Nucleus | 4 | 2008 | 2969 | 0.050 |
Why?
|
| Nucleoside-Phosphate Kinase | 1 | 2001 | 23 | 0.050 |
Why?
|
| Sirolimus | 3 | 2004 | 1564 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2005 | 596 | 0.050 |
Why?
|
| Chromatin | 1 | 2013 | 2934 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2010 | 1434 | 0.050 |
Why?
|
| Quality of Life | 1 | 2023 | 12804 | 0.050 |
Why?
|
| Disease Progression | 3 | 2008 | 13284 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2008 | 3144 | 0.050 |
Why?
|
| Kidney | 3 | 2013 | 7186 | 0.050 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2004 | 520 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2004 | 11366 | 0.050 |
Why?
|
| Administration, Oral | 3 | 2016 | 3913 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2007 | 996 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2010 | 1941 | 0.050 |
Why?
|
| Vitamin D | 2 | 2013 | 3223 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2012 | 1915 | 0.050 |
Why?
|
| Cloning, Molecular | 5 | 2013 | 4320 | 0.050 |
Why?
|
| Cell Communication | 1 | 2008 | 1621 | 0.050 |
Why?
|
| Genetic Variation | 4 | 2013 | 6544 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 2716 | 0.050 |
Why?
|
| Indazoles | 2 | 2012 | 289 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2014 | 1692 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2011 | 2575 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2004 | 491 | 0.050 |
Why?
|
| Paraffin | 1 | 1999 | 35 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 402 | 0.040 |
Why?
|
| Tissue Embedding | 1 | 1999 | 43 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2016 | 21827 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 40075 | 0.040 |
Why?
|
| Transgenes | 1 | 2003 | 1009 | 0.040 |
Why?
|
| Half-Life | 1 | 2000 | 661 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2297 | 0.040 |
Why?
|
| Placebos | 1 | 2004 | 1676 | 0.040 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2008 | 1375 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 182 | 0.040 |
Why?
|
| Crystallography, X-Ray | 2 | 2016 | 2011 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2012 | 250 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 871 | 0.040 |
Why?
|
| Sarcoma | 1 | 2010 | 1897 | 0.040 |
Why?
|
| DNA | 6 | 2015 | 7301 | 0.040 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 1998 | 76 | 0.040 |
Why?
|
| Sensitivity and Specificity | 4 | 2008 | 14722 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2009 | 118 | 0.040 |
Why?
|
| Retinoblastoma-Like Protein p107 | 1 | 1998 | 74 | 0.040 |
Why?
|
| Neoplasms, Experimental | 3 | 2010 | 1276 | 0.040 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 1999 | 111 | 0.040 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2018 | 113 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2001 | 686 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2002 | 1099 | 0.040 |
Why?
|
| Aspartic Acid | 1 | 2000 | 576 | 0.040 |
Why?
|
| Aged | 11 | 2019 | 163280 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2005 | 6622 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2019 | 270 | 0.040 |
Why?
|
| Algorithms | 3 | 2008 | 13881 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 478 | 0.040 |
Why?
|
| Genetic Drift | 1 | 2017 | 43 | 0.040 |
Why?
|
| Chromosomes, Human | 2 | 2012 | 457 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 17446 | 0.040 |
Why?
|
| User-Computer Interface | 1 | 2004 | 1431 | 0.040 |
Why?
|
| RNA Polymerase I | 1 | 1996 | 24 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2003 | 1172 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2018 | 349 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2006 | 3772 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 2703 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 1996 | 113 | 0.040 |
Why?
|
| Prognosis | 4 | 2008 | 29063 | 0.040 |
Why?
|
| Mice, Knockout | 4 | 2017 | 14557 | 0.040 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2016 | 82 | 0.030 |
Why?
|
| Breast | 2 | 2004 | 1969 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 1364 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2020 | 684 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 4420 | 0.030 |
Why?
|
| Cell Membrane | 1 | 2006 | 3748 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 5686 | 0.030 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2008 | 2214 | 0.030 |
Why?
|
| Biological Transport | 1 | 2000 | 2118 | 0.030 |
Why?
|
| Middle Aged | 11 | 2019 | 213383 | 0.030 |
Why?
|
| Cell Line, Transformed | 2 | 2011 | 898 | 0.030 |
Why?
|
| Karyotyping | 2 | 2008 | 1243 | 0.030 |
Why?
|
| RNA | 2 | 2003 | 2749 | 0.030 |
Why?
|
| Dogs | 1 | 2020 | 3912 | 0.030 |
Why?
|
| Caspase 8 | 1 | 2015 | 195 | 0.030 |
Why?
|
| Adult | 12 | 2016 | 214055 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.030 |
Why?
|
| Cell Separation | 2 | 2000 | 1751 | 0.030 |
Why?
|
| Sulfones | 1 | 2017 | 437 | 0.030 |
Why?
|
| Protein Stability | 1 | 2016 | 557 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2015 | 146 | 0.030 |
Why?
|
| Trypan Blue | 1 | 2013 | 21 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 4328 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Multigene Family | 2 | 2010 | 1102 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 157 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 88 | 0.030 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2013 | 59 | 0.030 |
Why?
|
| Mitosis | 2 | 2012 | 1208 | 0.030 |
Why?
|
| Databases, Genetic | 2 | 2016 | 1783 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 474 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2010 | 1157 | 0.030 |
Why?
|
| Radioligand Assay | 1 | 2013 | 374 | 0.030 |
Why?
|
| Phosphoenolpyruvate | 1 | 2012 | 16 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 6386 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2014 | 475 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 2014 | 254 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2013 | 201 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2016 | 1246 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2014 | 274 | 0.030 |
Why?
|
| Substrate Specificity | 3 | 2006 | 1801 | 0.030 |
Why?
|
| Tail | 1 | 2013 | 97 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2015 | 401 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2012 | 305 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2003 | 2635 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1312 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2013 | 156 | 0.030 |
Why?
|
| Topoisomerase Inhibitors | 1 | 2012 | 18 | 0.030 |
Why?
|
| Amino Acid Motifs | 2 | 2006 | 936 | 0.030 |
Why?
|
| Aged, 80 and over | 5 | 2006 | 57776 | 0.030 |
Why?
|
| Subcutaneous Tissue | 1 | 2013 | 135 | 0.030 |
Why?
|
| Acetamides | 1 | 2014 | 249 | 0.030 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 5181 | 0.030 |
Why?
|
| Ions | 1 | 2013 | 265 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 1996 | 551 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2005 | 464 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 633 | 0.030 |
Why?
|
| Carbon Isotopes | 1 | 2012 | 467 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2000 | 1788 | 0.030 |
Why?
|
| Acyltransferases | 1 | 2013 | 294 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2015 | 572 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2014 | 371 | 0.030 |
Why?
|
| Exons | 3 | 2005 | 2437 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2011 | 200 | 0.030 |
Why?
|
| Minerals | 1 | 2013 | 275 | 0.020 |
Why?
|
| Acetyltransferases | 2 | 2004 | 234 | 0.020 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 405 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 259 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2015 | 2050 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 380 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 479 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 6895 | 0.020 |
Why?
|
| Growth Plate | 1 | 2013 | 274 | 0.020 |
Why?
|
| Biological Availability | 1 | 2011 | 397 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 4149 | 0.020 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 1888 | 0.020 |
Why?
|
| Sex Factors | 1 | 2005 | 10397 | 0.020 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2010 | 61 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2011 | 130 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2010 | 4217 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 905 | 0.020 |
Why?
|
| Histone Acetyltransferases | 2 | 2004 | 336 | 0.020 |
Why?
|
| Models, Genetic | 3 | 2006 | 3494 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2006 | 3309 | 0.020 |
Why?
|
| Wnt1 Protein | 1 | 2010 | 118 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2008 | 11031 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2010 | 203 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 1701 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 713 | 0.020 |
Why?
|
| Amino Acids | 1 | 2016 | 1736 | 0.020 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2012 | 209 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2014 | 1792 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2010 | 2015 | 0.020 |
Why?
|
| Bone Development | 1 | 2013 | 483 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7322 | 0.020 |
Why?
|
| Aniline Compounds | 1 | 2014 | 986 | 0.020 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 635 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2010 | 565 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2013 | 739 | 0.020 |
Why?
|
| Conserved Sequence | 2 | 2007 | 1202 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1676 | 0.020 |
Why?
|
| Luciferases | 2 | 2005 | 733 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 849 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2012 | 591 | 0.020 |
Why?
|
| Tubulin | 1 | 2012 | 695 | 0.020 |
Why?
|
| Adenine | 1 | 2013 | 936 | 0.020 |
Why?
|
| Telomerase | 2 | 2004 | 730 | 0.020 |
Why?
|
| Nitriles | 1 | 2013 | 956 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 2019 | 0.020 |
Why?
|
| Prevalence | 1 | 2005 | 15226 | 0.020 |
Why?
|
| Biological Evolution | 1 | 1994 | 1076 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 675 | 0.020 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 2541 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 496 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 893 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2008 | 322 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2009 | 290 | 0.020 |
Why?
|
| Developmental Disabilities | 1 | 2016 | 1456 | 0.020 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2010 | 504 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2012 | 1133 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2010 | 810 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 380 | 0.020 |
Why?
|
| Nuclear Export Signals | 1 | 2006 | 9 | 0.020 |
Why?
|
| Insulin | 1 | 2002 | 6580 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2012 | 1730 | 0.020 |
Why?
|
| Tyrosine | 1 | 2011 | 1461 | 0.020 |
Why?
|
| Survival Rate | 2 | 2013 | 12788 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 553 | 0.020 |
Why?
|
| Psychomotor Disorders | 1 | 2007 | 152 | 0.020 |
Why?
|
| Femur | 1 | 2013 | 1297 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1157 | 0.020 |
Why?
|
| Risk Factors | 2 | 2005 | 72290 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 4034 | 0.020 |
Why?
|
| Nuclear Localization Signals | 1 | 2006 | 80 | 0.020 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2005 | 46 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1997 | 5974 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 15076 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 783 | 0.020 |
Why?
|
| Dictyostelium | 1 | 2006 | 75 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2006 | 147 | 0.020 |
Why?
|
| SH2 Domain-Containing Protein Tyrosine Phosphatases | 1 | 2004 | 45 | 0.020 |
Why?
|
| Chromosomes, Human, Y | 1 | 2006 | 148 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2006 | 249 | 0.020 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2006 | 209 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2006 | 436 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2005 | 162 | 0.020 |
Why?
|
| Restriction Mapping | 2 | 1996 | 878 | 0.020 |
Why?
|
| Osteosarcoma | 2 | 2005 | 881 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1799 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2004 | 53 | 0.020 |
Why?
|
| Cells | 1 | 2006 | 168 | 0.020 |
Why?
|
| Thermodynamics | 1 | 2006 | 596 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2007 | 769 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2010 | 2088 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4933 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2006 | 337 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2013 | 1377 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2005 | 719 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 573 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1861 | 0.020 |
Why?
|
| Hepatitis B, Chronic | 1 | 2008 | 393 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2005 | 279 | 0.010 |
Why?
|
| src Homology Domains | 1 | 2004 | 364 | 0.010 |
Why?
|
| Phosphoglycerate Kinase | 1 | 2003 | 68 | 0.010 |
Why?
|
| Genes, Neoplasm | 1 | 2005 | 376 | 0.010 |
Why?
|
| Acetylation | 1 | 2006 | 1085 | 0.010 |
Why?
|
| Cancer Care Facilities | 1 | 2006 | 402 | 0.010 |
Why?
|
| Cellular Apoptosis Susceptibility Protein | 1 | 2002 | 5 | 0.010 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 187 | 0.010 |
Why?
|
| Urothelium | 1 | 2005 | 277 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 4462 | 0.010 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2003 | 135 | 0.010 |
Why?
|
| Calmodulin | 1 | 2003 | 209 | 0.010 |
Why?
|
| Granulocytes | 1 | 2005 | 548 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2003 | 205 | 0.010 |
Why?
|
| Karyopherins | 1 | 2003 | 137 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2013 | 4161 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2006 | 853 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 595 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2002 | 278 | 0.010 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2003 | 77 | 0.010 |
Why?
|
| Mammary Glands, Animal | 1 | 2004 | 276 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2015 | 3589 | 0.010 |
Why?
|
| Body Fluids | 1 | 2004 | 319 | 0.010 |
Why?
|
| Benzothiazoles | 1 | 2003 | 248 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 422 | 0.010 |
Why?
|
| Transplantation Chimera | 1 | 2005 | 612 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2004 | 460 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 3760 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2004 | 430 | 0.010 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 1 | 2002 | 102 | 0.010 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 434 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2007 | 1189 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2009 | 3588 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2004 | 464 | 0.010 |
Why?
|
| Body Weight | 1 | 2013 | 4669 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 547 | 0.010 |
Why?
|
| Genes, abl | 1 | 2000 | 72 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2005 | 1547 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 154 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 192 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2000 | 347 | 0.010 |
Why?
|
| Child | 3 | 2016 | 77709 | 0.010 |
Why?
|
| CREB-Binding Protein | 1 | 2000 | 151 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 494 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2004 | 934 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 2505 | 0.010 |
Why?
|
| Hepatitis C, Chronic | 1 | 2008 | 1031 | 0.010 |
Why?
|
| Protozoan Proteins | 1 | 2006 | 827 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2005 | 1586 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 5708 | 0.010 |
Why?
|
| Japan | 1 | 2004 | 1360 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2008 | 1988 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2006 | 3128 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 1679 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 2256 | 0.010 |
Why?
|
| Astrocytes | 1 | 2006 | 1270 | 0.010 |
Why?
|
| Ubiquitins | 1 | 2000 | 384 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 1866 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 2699 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 4851 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 806 | 0.010 |
Why?
|
| Heterozygote | 1 | 2005 | 2804 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2004 | 1538 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 1686 | 0.010 |
Why?
|
| Neurons | 1 | 2016 | 9338 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2008 | 3086 | 0.010 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1997 | 225 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 1101 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 1996 | 191 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1999 | 1454 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 3616 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 1997 | 462 | 0.010 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 1524 | 0.010 |
Why?
|
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 31 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1995 | 222 | 0.010 |
Why?
|
| Seizures | 1 | 2007 | 2859 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1995 | 427 | 0.010 |
Why?
|
| Adolescent | 2 | 2016 | 85781 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2003 | 2494 | 0.010 |
Why?
|
| Introns | 1 | 1996 | 991 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 1994 | 263 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2016 | 41006 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 1994 | 295 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 1994 | 131 | 0.010 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 1992 | 31 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2006 | 3848 | 0.010 |
Why?
|
| Stem Cells | 1 | 2005 | 3567 | 0.010 |
Why?
|
| Cell Movement | 1 | 2004 | 5217 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1994 | 257 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2004 | 3444 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 1157 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 9274 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 12261 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 56430 | 0.010 |
Why?
|
| Plasmids | 1 | 1995 | 2307 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1994 | 2839 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2004 | 5102 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 77449 | 0.000 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1994 | 1341 | 0.000 |
Why?
|
| Lung | 1 | 2004 | 9856 | 0.000 |
Why?
|
| Pregnancy | 1 | 2004 | 29144 | 0.000 |
Why?
|
| Bone Neoplasms | 1 | 1995 | 2529 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2000 | 7181 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2003 | 23338 | 0.000 |
Why?
|
| Brain | 1 | 2007 | 26385 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 35421 | 0.000 |
Why?
|
| United States | 1 | 2004 | 69872 | 0.000 |
Why?
|